Created at	Source	Raw Value	Validated value
Dec. 12, 2022, 8 a.m.	usa	Frequency of Solicited AEs (Local and Systemic Reactions) Within 7 Days After Any Vaccination of the Primary Vaccination Series;Geometric Mean Titre (GMT) for Neutralizing Antibodies Against SARS-CoV-2 Determined by Wild-type Virus Neutralizing Assay	Frequency of Solicited AEs (Local and Systemic Reactions) Within 7 Days After Any Vaccination of the Primary Vaccination Series;Geometric Mean Titre (GMT) for Neutralizing Antibodies Against SARS-CoV-2 Determined by Wild-type Virus Neutralizing Assay
Nov. 22, 2022, noon	usa	None	None
March 27, 2022, 4 p.m.	usa	Frequency of Solicited AEs (Local and Systemic Reactions) Within 7 Days After Any Vaccination of the Primary Vaccination Series;Geometric Mean Titre (GMT) for Neutralizing Antibodies Against SARS-CoV-2 Determined by Wild-type Virus Neutralizing Assay	Frequency of Solicited AEs (Local and Systemic Reactions) Within 7 Days After Any Vaccination of the Primary Vaccination Series;Geometric Mean Titre (GMT) for Neutralizing Antibodies Against SARS-CoV-2 Determined by Wild-type Virus Neutralizing Assay
Nov. 1, 2021, noon	usa	Frequency and severity of solicited AEs (local and systemic reactions) within 7 days after any vaccination of the primary vaccination series;Geometric mean titre (GMT) for neutralizing antibodies against SARS-CoV-2 determined by wild-type virus neutralizing assay	Frequency and severity of solicited AEs (local and systemic reactions) within 7 days after any vaccination of the primary vaccination series;Geometric mean titre (GMT) for neutralizing antibodies against SARS-CoV-2 determined by wild-type virus neutralizing assay
Dec. 19, 2020, 12:31 a.m.	usa	Frequency and severity of solicited AEs (local and systemic reactions) within 7 days after any vaccination;Geometric mean titre (GMT) for neutralizing antibodies against SARS-CoV-2	Frequency and severity of solicited AEs (local and systemic reactions) within 7 days after any vaccination;Geometric mean titre (GMT) for neutralizing antibodies against SARS-CoV-2